Financial Enhancement Group LLC Chemo Centryx, Inc. Transaction History
Financial Enhancement Group LLC
- $559 Million
- Q4 2024
Shares
2 transactions
Others Institutions Holding CCXI
# of Institutions
6Shares Held
66.3KCall Options Held
0Put Options Held
0-
S. Muoio & Co. LLC New York, NY58KShares$03.96% of portfolio
-
Sarissa Consulting LLC Santa Monica, CA8KShares$00.43% of portfolio
-
Wipfli Financial Advisors Llc,216Shares$00.0% of portfolio
-
Exane Derivatives92Shares$00.0% of portfolio
-
Four Thought Financial, LLC Venice, FL24Shares$00.0% of portfolio
About ChemoCentryx, Inc.
- Ticker CCXI
- Exchange NASDAQ
- Shares Outstandng 71,919,696
- Market Cap $3.68M
- Description
- ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...